Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 2
2002 3
2003 3
2004 2
2005 3
2007 6
2008 3
2009 6
2010 4
2011 3
2012 3
2013 6
2014 3
2015 5
2016 5
2017 4
2018 15
2019 13
2020 4
2021 7
2022 9
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Neurostimulation for Parkinson's disease with early motor complications.
Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Hälbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, Maltête D, Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, Krüger R, Pinsker MO, Amtage F, Régis JM, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade-Brittinger C, Deuschl G; EARLYSTIM Study Group. Schuepbach WM, et al. Among authors: witjas t. N Engl J Med. 2013 Feb 14;368(7):610-22. doi: 10.1056/NEJMoa1205158. N Engl J Med. 2013. PMID: 23406026 Free article. Clinical Trial.
Radiosurgical Subthalamic Nucleotomy.
Régis J, Carron R, Witjas T. Régis J, et al. Among authors: witjas t. Prog Neurol Surg. 2018;33:158-167. doi: 10.1159/000481084. Epub 2018 Jan 12. Prog Neurol Surg. 2018. PMID: 29332081 Review.
[No motor signs in Parkinson's disease].
Azulay JP, Witjas T, Eusebio A. Azulay JP, et al. Among authors: witjas t. Presse Med. 2017 Mar;46(2 Pt 1):195-201. doi: 10.1016/j.lpm.2016.11.015. Epub 2017 Jan 4. Presse Med. 2017. PMID: 28063757 Review. French.
News and controversies regarding essential tremor.
Boutin E, Vaugoyeau M, Eusebio A, Azulay JP, Witjas T. Boutin E, et al. Among authors: witjas t. Rev Neurol (Paris). 2015 May;171(5):415-25. doi: 10.1016/j.neurol.2015.02.007. Epub 2015 Apr 7. Rev Neurol (Paris). 2015. PMID: 25862370 Review.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Results of a Randomized Clinical Trial of Speech After Early Neurostimulation in Parkinson's Disease.
Pinto S, Nebel A, Rau J, Espesser R, Maillochon P, Niebuhr O, Krack P, Witjas T, Ghio A, Cuartero MC, Timmermann L, Schnitzler A, Hesekamp H, Meier N, Müllner J, Hälbig TD, Möller B, Paschen S, Paschen L, Volkmann J, Barbe MT, Fink GR, Becker J, Reker P, Kühn AA, Schneider GH, Fraix V, Seigneuret E, Kistner A, Rascol O, Brefel-Courbon C, Ory-Magne F, Hartmann CJ, Wojtecki L, Fradet A, Maltête D, Damier P, Le Dily S, Sixel-Döring F, Benecke P, Weiss D, Wächter T, Pinsker MO, Régis J, Thobois S, Polo G, Houeto JL, Hartmann A, Knudsen K, Vidailhet M, Schüpbach M, Deuschl G; EARLYSTIM Study Group. Pinto S, et al. Among authors: witjas t. Mov Disord. 2023 Feb;38(2):212-222. doi: 10.1002/mds.29282. Epub 2022 Dec 3. Mov Disord. 2023. PMID: 36461899 Clinical Trial.
Addictive behaviors and Parkinson's disease.
Witjas T, Eusebio A, Fluchère F, Azulay JP. Witjas T, et al. Rev Neurol (Paris). 2012 Aug-Sep;168(8-9):624-33. doi: 10.1016/j.neurol.2012.06.014. Epub 2012 Aug 24. Rev Neurol (Paris). 2012. PMID: 22921247 Review.
[Non-motor fluctuations in Parkinson's disease].
Witjas T, Kaphan E, Azulay JP. Witjas T, et al. Rev Neurol (Paris). 2007 Sep;163(8-9):846-50. doi: 10.1016/s0035-3787(07)91470-8. Rev Neurol (Paris). 2007. PMID: 17878814 Review. French.
101 results